Keywords: |
platelet derived growth factor; vasculotropin; cancer chemotherapy; cancer survival; protein expression; unclassified drug; androgen; clinical trial; disease course; sunitinib; advanced cancer; drug safety; risk benefit analysis; alpha interferon; cancer staging; cancer diagnosis; protein function; protein localization; stem cell factor; interleukin 2; unindexed drug; reverse transcription polymerase chain reaction; dendritic cell; granulocyte macrophage colony stimulating factor; antineoplastic activity; kidney carcinoma; monoclonal antibody; protein tyrosine kinase inhibitor; prostate cancer; in situ hybridization; prostate specific membrane antigen; immune response; immunotherapy; immunoglobulin g; cancer vaccine; drug mechanism; kidney surgery; immunogenicity; cancer immunization; membrane protein; drug response; cellular distribution; hormonal therapy; antiandrogen; kidney cancer; flt3 ligand; antiangiogenic activity; neovascularization (pathology); glycoprotein; carbohydrate antigen; fibroblast growth factor; antiestrogen; risk management; fumagillol chloroacetylcarbamate; immunoglobulin m; angiostatin; qs 21; gestagen; heat shock protein; endostatin; metalloproteinase inhibitor; 5 amino 1 [3,5 dichloro 4 (4 chlorobenzoyl)benzyl] 1h 1,2,3 triazole 4 carboxamide
|